CD47 and anemia: As shown by others and us (20, 47, 52–55), this targeted approach has the advantage of avoiding potential side effects due to the otherwise arbitrary blockade of CD47 on normal cells, as observed for other CD47-targeting approaches, with anemia and thrombocytopenia being the most frequent adverse events associated with CD47 mAbs (51).